{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:31:26Z","timestamp":1767987086446,"version":"3.49.0"},"reference-count":230,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmech.2023.115875","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T20:53:01Z","timestamp":1697489581000},"page":"115875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Advances in research on potential inhibitors of multiple myeloma"],"prefix":"10.1016","volume":"262","author":[{"given":"Guoyuan","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingmiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-0282","authenticated-orcid":false,"given":"Jianyou","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115875_bib1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2023.115875_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000734","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma","volume":"8","author":"Shah","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejmech.2023.115875_bib3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/14656566.2018.1441287","article-title":"Proteasome inhibitors for the treatment of multiple myeloma","volume":"19","author":"Scalzulli","year":"2018","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2023.115875_bib4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17474086.2021.1905513","article-title":"Immunomodulators in newly diagnosed multiple myeloma: current and future concepts","volume":"14","author":"Delforge","year":"2021","journal-title":"Expet Rev. Hematol."},{"key":"10.1016\/j.ejmech.2023.115875_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-018-3465-8","article-title":"Glucocorticoids in multiple myeloma: past, present, and future","volume":"98","author":"Burwick","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejmech.2023.115875_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Rodriguez-Otero","year":"2021","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2023.115875_bib7","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115875_bib8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-022-00695-5","article-title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee","volume":"12","author":"Kumar","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejmech.2023.115875_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejmech.2023.115875_bib10","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41375-019-0517-6","article-title":"Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma","volume":"33","author":"Landgren","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2023.115875_bib11","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.1182\/blood-2018-99-114019","article-title":"Efficacy and safety of histone deacetylase inhibitors in multiple myeloma - a systematic review of early phase clinical trials","volume":"132","author":"Samuel","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115875_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-020-00350-x","article-title":"Immune-based therapies in the management of multiple myeloma","volume":"10","author":"Zanwar","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejmech.2023.115875_bib13","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab mafodotin: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115875_bib14","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40265-021-01522-0","article-title":"Melphalan flufenamide (melflufen): first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115875_bib15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2147\/ITT.S306103","article-title":"Immunotherapy of multiple myeloma: promise and challenges","volume":"10","author":"Abramson","year":"2021","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.ejmech.2023.115875_bib16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2023.115875_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107579","article-title":"The proteasome as a druggable target with multiple therapeutic potentialities: cutting and non-cutting edges","volume":"213","author":"Tundo","year":"2020","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115875_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergen.2020.12.001","article-title":"Genetic variants as biomarkers for progression and resistance in multiple myeloma","volume":"252","author":"Montel","year":"2021","journal-title":"Cancer Genetics"},{"key":"10.1016\/j.ejmech.2023.115875_bib19","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int. J. Hematol."},{"issue":"19","key":"10.1016\/j.ejmech.2023.115875_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5306\/wjco.v10.i9.303","article-title":"Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma","volume":"10","author":"Zhou","year":"2019","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115875_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15210","article-title":"Resistance to proteasome inhibitors and other targeted therapies in myeloma","volume":"182","author":"Wallington-Beddoe","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2023.115875_bib22","volume":"33","author":"Liu","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115875_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/17474086.2020.1711730","article-title":"Heat shock proteins as a new, promising target of multiple myeloma therapy","volume":"13","author":"Grosicki","year":"2020","journal-title":"Expet Rev. Hematol."},{"key":"10.1016\/j.ejmech.2023.115875_bib24","doi-asserted-by":"crossref","first-page":"7627","DOI":"10.3390\/ijms23147627","article-title":"Targeting the microenvironment for treating multiple myeloma","volume":"23","author":"Neumeister","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115875_bib25","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115875_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810222","article-title":"The new microtubule-targeting agent SIX2G induces immunogenic cell death in multiple myeloma","volume":"23","author":"Grillone","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115875_bib27","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115875_bib28","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/ddr.21962","article-title":"Novel insights on [1,2]oxazolo[5,4-e]isoindoles on multidrug resistant acute myeloid leukemia cell line","volume":"83","author":"Labbozzetta","year":"2022","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2023.115875_bib29","series-title":"Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors","author":"LaPlante","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115875_bib30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.blre.2013.10.002","article-title":"Targeting the ubiquitin proteasome system in haematological malignancies","volume":"27","author":"Crawford","year":"2013","journal-title":"Blood Rev."},{"key":"10.1016\/j.ejmech.2023.115875_bib31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.biocel.2018.06.001","article-title":"Ubiquitination: friend and foe in cancer","volume":"101","author":"Mansour","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115875_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","article-title":"The role of ubiquitination in tumorigenesis and targeted drug discovery","volume":"5","author":"Deng","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2023.115875_bib33","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.tig.2020.12.005","article-title":"Histone ubiquitination: an integrative signaling platform in genome stability","volume":"37","author":"Mattiroli","year":"2021","journal-title":"Trends Genet."},{"key":"10.1016\/j.ejmech.2023.115875_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01751","article-title":"The membrane-associated MARCH E3 ligase family: emerging roles in immune regulation","volume":"10","author":"Lin","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2023.115875_bib35","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1042\/BST0370937","article-title":"The emerging complexity of protein ubiquitination","volume":"37","author":"Komander","year":"2009","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejmech.2023.115875_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbamcr.2013.09.009","article-title":"The ubiquitin\u2013proteasome-system","volume":"1843","author":"Sommer","year":"2014","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.ejmech.2023.115875_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01080","article-title":"Inhibition of ubiquitin-specific proteases as a novel anticancer therapeutic strategy","volume":"9","author":"Yuan","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115875_bib38","series-title":"Ubiquitin System","author":"Nakamura","year":"2018"},{"key":"10.1016\/j.ejmech.2023.115875_bib39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/EBC20160001","article-title":"Bett, Proteostasis regulation by the ubiquitin system","volume":"60","author":"John","year":"2016","journal-title":"Essays Biochem."},{"key":"10.1016\/j.ejmech.2023.115875_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cbpa.2018.05.004","article-title":"Targeted protein degradation and the enzymology of degraders","volume":"44","author":"Fisher","year":"2018","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"No 6","key":"10.1016\/j.ejmech.2023.115875_bib41","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.6658","article-title":"Novel strategies to target the ubiquitin proteasome system in multiple myeloma","volume":"7","author":"Lub","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2023.115875_bib42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome inhibitor drugs","volume":"60","author":"Fricker","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2023.115875_bib43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-020-00421-2","article-title":"Targeting ubiquitin signaling for cancer immunotherapy","volume":"6","author":"Zhou","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2023.115875_bib44","article-title":"HECT E3 ubiquitin ligases \u2013 emerging insights into their biological roles and disease relevance","volume":"133","author":"Wang","year":"2020","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejmech.2023.115875_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2023.115875_bib46","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity","volume":"7","author":"Li","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115875_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D\u2013CDK4 kinase destabilizes PD-L1 via cullin 3\u2013SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115875_bib48","series-title":"Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy","first-page":"295","article-title":"Regulation of cancer immune checkpoint: mono- and poly-ubiquitination: tags for fate","author":"Yao","year":"2020"},{"key":"10.1016\/j.ejmech.2023.115875_bib49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41392-020-00418-x","article-title":"Targeting the ubiquitination\/deubiquitination process to regulate immune checkpoint pathways","volume":"6","author":"Liu","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2023.115875_bib50","doi-asserted-by":"crossref","first-page":"7135","DOI":"10.4049\/jimmunol.173.12.7135","article-title":"Cutting edge: cbl-b: one of the key molecules tuning CD28- and CTLA-4-mediated T cell costimulation","volume":"173","author":"Li","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115875_bib51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1742-4658.2010.07922.x","article-title":"GRAIL: a unique mediator of CD4 T-lymphocyte unresponsiveness","volume":"278","author":"Whiting","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2023.115875_bib52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/jid.2012.265","article-title":"Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for s\u00e9zary syndrome","volume":"133","author":"Gibson","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejmech.2023.115875_bib53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.nbt.2016.12.002","article-title":"Overview of the membrane-associated RING-CH (MARCH) E3 ligase family","volume":"38","author":"Bauer","year":"2017","journal-title":"N. Biotech."},{"key":"10.1016\/j.ejmech.2023.115875_bib54","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1172\/JCI12432","article-title":"A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation","volume":"107","author":"Coscoy","year":"2001","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2023.115875_bib55","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1083\/jcb.200111010","article-title":"A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition","volume":"155","author":"Coscoy","year":"2001","journal-title":"JCB (J. Cell Biol.)"},{"key":"10.1016\/j.ejmech.2023.115875_bib56","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/eji.201847848","article-title":"The Ubiquitin-proteasome pathway regulates Nectin2\/CD112 expression and impairs NK cell recognition and killing","volume":"49","author":"Molfetta","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115875_bib57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-065X.2012.01108.x","article-title":"Ubiquitination in signaling to and activation of IKK","volume":"246","author":"Chen","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejmech.2023.115875_bib58","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/s41467-018-04013-1","article-title":"The molecular basis of JAK\/STAT inhibition by SOCS1","volume":"9","author":"Liau","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115875_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114053","article-title":"A review on the treatment of multiple myeloma with small molecular agents in the past five years","volume":"229","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115875_bib60","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature08657","article-title":"Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks","volume":"462","author":"Galanty","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115875_bib61","series-title":"Cells","article-title":"Potential of E3 ubiquitin ligases in cancer immunity: opportunities and challenges","author":"Ye","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115875_bib62","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s12272-020-01281-8","article-title":"Ubiquitin\u2013proteasome system (UPS) as a target for anticancer treatment","volume":"43","author":"Park","year":"2020","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.ejmech.2023.115875_bib63","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.2174\/0929867328666210806113949","article-title":"Targeted protein degradation and regulation with molecular glue: past and recent discoveries","volume":"29","author":"Fang","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115875_bib64","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1038\/s41388-020-1336-y","article-title":"PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics","volume":"39","author":"Khan","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2023.115875_bib65","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1111\/ajco.13744","article-title":"A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors","volume":"18","author":"Morita","year":"2022","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115875_bib66","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/nm.4229","article-title":"IAP antagonists induce anti-tumor immunity in multiple myeloma","volume":"22","author":"Chesi","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.115875_bib67","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115875_bib68","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood-2013-08-521914","article-title":"MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells","volume":"123","author":"Gu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115875_bib69","doi-asserted-by":"crossref","first-page":"6161","DOI":"10.1021\/acs.jmedchem.1c00242","article-title":"Development of potent NEDD8-activating enzyme inhibitors bearing a pyrimidotriazole scaffold","volume":"64","author":"Xiong","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115875_bib70","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-15-1237","article-title":"Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed\/refractory multiple myeloma or lymphoma","volume":"22","author":"Shah","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115875_bib71","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41589-020-0620-z","article-title":"Prospecting for molecular glues","volume":"16","author":"den Besten","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115875_bib72","article-title":"Targeting cereblon in hematologic malignancies","author":"Fuchs","year":"2022","journal-title":"Blood Rev."},{"key":"10.1016\/j.ejmech.2023.115875_bib73","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/1078-0432.CCR-18-1203","article-title":"A first-in-human study of novel cereblon modulator avadomide (CC-122) in advanced malignancies","volume":"25","author":"Rasco","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115875_bib74","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.ejmech.2023.115875_bib75","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020003597","article-title":"IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-\u03baB\u2013 and caspase-8\u2013dependent mechanisms","volume":"5","author":"Zhou","year":"2021","journal-title":"Blood Advances"},{"key":"10.1016\/j.ejmech.2023.115875_bib76","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10637-019-00840-1","article-title":"Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma","volume":"38","author":"Gluck","year":"2020","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2023.115875_bib77","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/bjh.18200","article-title":"Bendamustine in combination with pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a phase II trial","volume":"198","author":"Kumar","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2023.115875_bib78","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13046-022-02363-9","article-title":"CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies","volume":"41","author":"Bruno","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115875_bib79","first-page":"197","article-title":"Withaferin A inhibits cell proliferation of U266B1 and IM-9 human myeloma cells by inducing intrinsic apoptosis","volume":"69","author":"Li","year":"2022","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.ejmech.2023.115875_bib80","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/14796694.3.2.191","article-title":"Deubiquitinating enzymes as novel anticancer targets","volume":"3","author":"Nicholson","year":"2007","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejmech.2023.115875_bib81","series-title":"Cancer Gene Networks","first-page":"49","article-title":"Targeting deubiquitinating enzymes and autophagy in cancer","author":"Mooneyham","year":"2017"},{"key":"10.1016\/j.ejmech.2023.115875_bib82","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5483\/BMBRep.2019.52.3.048","article-title":"Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities?","volume":"52","author":"Poondla","year":"2019","journal-title":"BMB Rep"},{"key":"10.1016\/j.ejmech.2023.115875_bib83","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2014-10-605584","article-title":"Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies","volume":"125","author":"Peterson","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115875_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.bej.2020.107834","article-title":"Characterization of PMI-5011 on the regulation of deubiquitinating enzyme activity in multiple myeloma cell extracts","volume":"166","author":"Vaithiyanathan","year":"2021","journal-title":"Biochem. Eng. J."},{"key":"10.1016\/j.ejmech.2023.115875_bib85","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-16-2692","article-title":"Blockade of deubiquitylating enzyme USP1 inhibits DNA repair and triggers apoptosis in multiple myeloma cells","volume":"23","author":"Das","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115875_bib86","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1476-4598-12-91","article-title":"USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy","volume":"12","author":"Garc\u00eda-Santisteban","year":"2013","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2023.115875_bib87","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1158\/1535-7163.MCT-13-0103-T","article-title":"Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells","volume":"12","author":"Mistry","year":"2013","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2023.115875_bib88","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/s41401-019-0249-1","article-title":"Mebendazole elicits potent antimyeloma activity by inhibiting the USP5\/c-Maf axis","volume":"40","author":"Chen","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2023.115875_bib89","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1074\/jbc.RA119.010724","article-title":"The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival","volume":"295","author":"He","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115875_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd6263","article-title":"Targeting oncoproteins with a positive selection assay for protein degraders","volume":"7","author":"Koduri","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2023.115875_bib91","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s10637-020-00915-4","article-title":"Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and\/or refractory multiple myeloma","volume":"38","author":"Rowinsky","year":"2020","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2023.115875_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223807","article-title":"Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15","volume":"14","author":"Mofers","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115875_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107526","article-title":"Exploring the proteasome system: a novel concept of proteasome inhibition and regulation","volume":"211","author":"Wang","year":"2020","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115875_bib94","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.tibs.2018.06.005","article-title":"Quality control in the endoplasmic reticulum: crosstalk between ERAD and UPR pathways","volume":"43","author":"Hwang","year":"2018","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2023.115875_bib95","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/14656566.2021.1999411","article-title":"Nonselective proteasome inhibitors in multiple myeloma and future perspectives","volume":"23","author":"Gavriatopoulou","year":"2022","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2023.115875_bib96","series-title":"Site-Specific Proteasome Inhibitors","author":"Kisselev","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115875_bib97","series-title":"Epidemiology, Staging, and Management of Multiple Myeloma","author":"Padala","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115875_bib98","doi-asserted-by":"crossref","first-page":"C451","DOI":"10.1152\/ajpcell.00286.2019","article-title":"Proteasome inhibition in multiple myeloma: lessons for other cancers, American journal of physiology","volume":"318","author":"Saavedra-Garc\u00eda","year":"2020","journal-title":"Cell physiology"},{"key":"10.1016\/j.ejmech.2023.115875_bib99","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.blre.2018.11.003","article-title":"The impact of NF-\u03baB signaling on pathogenesis and current treatment strategies in multiple myeloma","volume":"34","author":"Vr\u00e1bel","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.ejmech.2023.115875_bib100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/ajco.13459","article-title":"Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma","volume":"17","author":"Bai","year":"2021","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115875_bib101","doi-asserted-by":"crossref","first-page":"C451","DOI":"10.1152\/ajpcell.00286.2019","article-title":"Proteasome inhibition in multiple myeloma: lessons for other cancers","volume":"318","author":"Saavedra-Garc\u00eda","year":"2019","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejmech.2023.115875_bib102","doi-asserted-by":"crossref","first-page":"11127","DOI":"10.1021\/acs.jmedchem.8b01201","volume":"61","author":"Johnson","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115875_bib103","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/bjh.14987","article-title":"A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results","volume":"180","author":"Spencer","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2023.115875_bib104","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/neuonc\/nov299","article-title":"Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier","volume":"18","author":"Di","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2023.115875_bib105","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/bjh.14498","article-title":"Marizomib for central nervous system-multiple myeloma","volume":"177","author":"Badros","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2023.115875_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101465","article-title":"Advances in the treatment of extramedullary disease in multiple myeloma","volume":"22","author":"Li","year":"2022","journal-title":"Translational Oncology"},{"key":"10.1016\/j.ejmech.2023.115875_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100663","article-title":"Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance","volume":"48","author":"Narayanan","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2023.115875_bib108","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an international myeloma working group mass spectrometry committee report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejmech.2023.115875_bib109","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/1541-7786.MCR-19-0852","article-title":"Polycomb-like protein 3 induces proliferation and drug resistance in multiple myeloma and is regulated by miRNA-15a","volume":"18","author":"Yu","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115875_bib110","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13045-021-01217-9","article-title":"WDR26 and MTF2 are therapeutic targets in multiple myeloma","volume":"14","author":"Sun","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2023.115875_bib111","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23910","article-title":"PHD finger protein 19 expression in multiple myeloma: Association with clinical features, induction therapy outcome, disease progression, and survival","volume":"35","author":"Li","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.ejmech.2023.115875_bib112","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.3390\/ijms222212234","article-title":"Ferroptosis induction in multiple myeloma cells triggers DNA methylation and histone modification changes associated with cellular senescence","volume":"22","author":"Logie","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115875_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106499","article-title":"Up-regulation of multidrug resistance protein MDR1\/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs","volume":"101","author":"Byrgazov","year":"2021","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2023.115875_bib114","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/17474086.2020.1830372","article-title":"Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma","volume":"13","author":"Ninkovic","year":"2020","journal-title":"Expet Rev. Hematol."},{"key":"10.1016\/j.ejmech.2023.115875_bib115","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000505992","article-title":"The association between metabolic syndrome and multiple myeloma","volume":"144","author":"Ragbourne","year":"2021","journal-title":"Acta Haematol."},{"key":"10.1016\/j.ejmech.2023.115875_bib116","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ccell.2021.03.010","article-title":"Targeting cell-cycle machinery in cancer","volume":"39","author":"Suski","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2023.115875_bib117","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1158\/0008-5472.CAN-20-1357","article-title":"FAM46C and FNDC3A are multiple myeloma tumor suppressors that act in concert to impair clearing of protein aggregates and autophagy","volume":"80","author":"Manfrini","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115875_bib118","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41375-021-01483-z","article-title":"Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms","volume":"36","author":"Balasubramanian","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2023.115875_bib119","first-page":"1513","volume":"271","author":"G\u00f6rlich","year":"1996","journal-title":"Nucleocytoplasmic Transport, Science"},{"key":"10.1016\/j.ejmech.2023.115875_bib120","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0092-8674(00)80926-5","article-title":"Nucleocytoplasmic transport: the last 200 nanometers","volume":"92","author":"Ohno","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115875_bib121","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0092-8674(92)90635-P","article-title":"Architecture and design of the nuclear pore complex","volume":"69","author":"Hinshaw","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115875_bib122","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1074\/jbc.M008522200","article-title":"Dissection of a nuclear localization signal","volume":"276","author":"Hodel","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115875_bib123","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1 - from biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115875_bib124","doi-asserted-by":"crossref","first-page":"78896","DOI":"10.18632\/oncotarget.12969","article-title":"XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I\u03baB\u03b1 and overcomes acquired proteasome inhibitor resistance in human multiple myeloma","volume":"7","author":"Turner","year":"2016","journal-title":"Oncotarget"},{"issue":"No 48","key":"10.1016\/j.ejmech.2023.115875_bib125","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.12969","article-title":"XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I\u03baB\u03b1 and overcomes acquired proteasome inhibitor resistance in human multiple myeloma","volume":"7","author":"Turner","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2023.115875_bib126","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor\u2013dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115875_bib127","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41416-021-01608-2","article-title":"Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients","volume":"126","author":"Gasparetto","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2023.115875_bib128","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.2147\/OTT.S227166","article-title":"Clinical utility of selinexor\/dexamethasone in patients with relapsed or refractory multiple myeloma: a review of current evidence and patient selection","volume":"13","author":"Malandrakis","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2023.115875_bib129","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14656566.2019.1707184","article-title":"Selinexor for the treatment of multiple myeloma","volume":"21","author":"Podar","year":"2020","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2023.115875_bib130","doi-asserted-by":"crossref","DOI":"10.21037\/sci.2019.02.03","article-title":"The past, present, and future of CRM1\/XPO1 inhibitors","volume":"6","author":"Wang","year":"2019","journal-title":"Stem Cell Invest."},{"key":"10.1016\/j.ejmech.2023.115875_bib131","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1073\/pnas.1217203110","article-title":"Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1","volume":"110","author":"Sun","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2023.115875_bib132","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/bjc.1996.415","article-title":"Phase I trial of elactocin","volume":"74","author":"Newlands","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2023.115875_bib133","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ceb.2019.01.001","article-title":"Inhibitors of nuclear transport","volume":"58","author":"Jans","year":"2019","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115875_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114257","article-title":"Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells","volume":"235","author":"Qu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115875_bib135","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s11523-020-00758-2","article-title":"Targeting nuclear export proteins in multiple myeloma therapy","volume":"15","author":"Theodoropoulos","year":"2020","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.ejmech.2023.115875_bib136","doi-asserted-by":"crossref","first-page":"E54","DOI":"10.1002\/ajh.26420","article-title":"A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma","volume":"97","author":"Cornell","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2023.115875_bib137","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41584-020-00544-4","article-title":"Toll-like receptor signalling in B cells during systemic lupus erythematosus","volume":"17","author":"Fillatreau","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2023.115875_bib138","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1021\/acs.accounts.9b00631","article-title":"Small-molecule modulators of toll-like receptors","volume":"53","author":"Wang","year":"2020","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2023.115875_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114992","article-title":"Toll-like receptors: new targets for multiple myeloma treatment?","volume":"199","author":"Akesolo","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115875_bib140","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9914854","article-title":"Toll-like receptors: general molecular and structural biology","volume":"2021","author":"Behzadi","year":"2021","journal-title":"Journal of Immunology Research"},{"key":"10.1016\/j.ejmech.2023.115875_bib141","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/imt-2019-0096","article-title":"Toll-like receptors as a therapeutic target in cancer, infections and inflammatory diseases","volume":"12","author":"Fl\u00f3rez-\u00c1lvarez","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejmech.2023.115875_bib142","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/2045860","article-title":"Toll-like receptors in natural killer cells and their application for immunotherapy","volume":"2020","author":"Noh","year":"2020","journal-title":"Journal of Immunology Research"},{"key":"10.1016\/j.ejmech.2023.115875_bib143","series-title":"Tumor Microenvironment: Signaling Pathways \u2013 Part A","first-page":"81","article-title":"Toll-like receptors signaling in the tumor microenvironment","author":"McCall","year":"2020"},{"key":"10.1016\/j.ejmech.2023.115875_bib144","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/iub.2412","article-title":"Toll-like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists","volume":"73","author":"Keshavarz","year":"2021","journal-title":"IUBMB Life"},{"key":"10.1016\/j.ejmech.2023.115875_bib145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2020.04.002","article-title":"Toll-like receptors: triggers of regulated cell death and promising targets for cancer therapy","volume":"223","author":"Yang","year":"2020","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ejmech.2023.115875_bib146","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1541-7786.MCR-16-0293","article-title":"Combined TRAF6 targeting and proteasome blockade has anti-myeloma and anti-bone resorptive effects","volume":"15","author":"Chen","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115875_bib147","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2141.2010.08284.x","article-title":"Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-\u03baB","volume":"150","author":"Xu","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2023.115875_bib148","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1189\/jlb.3A1116-492R","article-title":"TLR10 suppresses the activation and differentiation of monocytes with effects on DC-mediated adaptive immune responses","volume":"101","author":"Hess","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ejmech.2023.115875_bib149","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/0008-5472.CAN-11-0188","article-title":"Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma","volume":"72","author":"Corre","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115875_bib150","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s10753-021-01588-8","article-title":"TLR4-IN-C34 inhibits lipopolysaccharide-stimulated inflammatory responses via downregulating TLR4\/MyD88\/NF-\u03baB\/NLRP3 signaling pathway and reducing ROS generation in BV2 cells","volume":"45","author":"Zhang","year":"2022","journal-title":"Inflammation"},{"key":"10.1016\/j.ejmech.2023.115875_bib151","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1182\/bloodadvances.2020003704","article-title":"Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth","volume":"6","author":"Lemaitre","year":"2022","journal-title":"Blood Advances"},{"key":"10.1016\/j.ejmech.2023.115875_bib152","series-title":"TLR4 Signaling and Heme Oxygenase-1\/Carbon Monoxide Pathway Crosstalk Induces Resiliency of Myeloma Plasma Cells to Bortezomib Treatment","author":"Scandura","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115875_bib153","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.2174\/1389450123666220920111841","article-title":"Targeted covalent inhibition: a prospective way to develop novel HSP90 C-terminal inhibitor","volume":"23","author":"Liu","year":"2022","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2023.115875_bib154","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.apsb.2020.11.015","article-title":"The disruption of protein\u2212protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition","volume":"11","author":"Serwetnyk","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115875_bib155","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"Trepel","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115875_bib156","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjh.16569","article-title":"The 60-kDa heat shock protein regulates energy rearrangement and protein synthesis to promote proliferation of multiple myeloma cells","volume":"190","author":"Wu","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2023.115875_bib157","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10238-019-00587-2","article-title":"Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells","volume":"20","author":"Tabata","year":"2020","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.ejmech.2023.115875_bib158","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/bjc.2017.302","article-title":"A phase I\/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed\/refractory multiple myeloma","volume":"117","author":"Cavenagh","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2023.115875_bib159","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.3324\/haematol.2018.207704","article-title":"A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis","volume":"104","author":"Lenka","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2023.115875_bib160","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.chembiol.2022.06.010","article-title":"Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma","volume":"29","author":"Ferguson","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115875_bib161","series-title":"Cells","article-title":"Gli proteins: regulation in development and cancer","author":"Niewiadomski","year":"2019"},{"key":"10.1016\/j.ejmech.2023.115875_bib162","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s10637-021-01187-2","article-title":"Advances in glioma-associated oncogene (GLI) inhibitors for cancer therapy","volume":"40","author":"Zhang","year":"2022","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2023.115875_bib163","series-title":"Cells","article-title":"Canonical Hedgehog pathway and noncanonical GLI transcription factor activation in cancer","author":"Suchors","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115875_bib164","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1080\/15384101.2020.1792686","article-title":"A Gli inhibitor GANT61 suppresses cell proliferation, promotes cell apoptosis and induces G1\/G0 cycle retardation with a dose- and time-dependent manner through inhibiting Notch pathway in multiple myeloma","volume":"19","author":"Zhang","year":"2020","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2023.115875_bib165","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00018-020-03627-3","article-title":"Complex crosstalk of Notch and Hedgehog signalling during the development of the central nervous system","volume":"78","author":"Jacobs","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2023.115875_bib166","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41392-022-00934-y","article-title":"Notch signaling pathway: architecture, disease, and therapeutics","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2023.115875_bib167","series-title":"Notch Signaling in Embryology and Cancer: Notch Signaling in Cancer","first-page":"201","article-title":"Notch pathway: a journey from notching phenotypes to cancer immunotherapy","author":"Monticone","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115875_bib168","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3324\/haematol.2021.279716","article-title":"Extracellular vesicles mediate the communication between multiple myeloma and bone marrow microenvironment in a NOTCH dependent way","volume":"107","author":"Giannandrea","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2023.115875_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100785","article-title":"Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction","volume":"28","author":"Sabol","year":"2022","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejmech.2023.115875_bib170","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1080\/07391102.2017.1396255","article-title":"Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents","volume":"36","author":"Balakumar","year":"2018","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2023.115875_bib171","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.2174\/1871520622666220119093105","article-title":"Role of KSP inhibitors as anti-cancer therapeutics: an update","volume":"22","author":"Chamariya","year":"2022","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115875_bib172","doi-asserted-by":"crossref","first-page":"FSO778","DOI":"10.2144\/fsoa-2021-0116","article-title":"Kinesin spindle protein inhibitors in cancer: from high throughput screening to novel therapeutic strategies","volume":"8","author":"Shahin","year":"2022","journal-title":"Future Science OA"},{"key":"10.1016\/j.ejmech.2023.115875_bib173","doi-asserted-by":"crossref","first-page":"571","DOI":"10.5483\/BMBRep.2015.48.10.015","article-title":"KSP inhibitor SB743921 induces death of multiple myeloma cells via inhibition of the NF-\u03baB signaling pathway","volume":"48","author":"Song","year":"2015","journal-title":"BMB Rep"},{"key":"10.1016\/j.ejmech.2023.115875_bib174","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1002\/cncr.30892","article-title":"A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed\/refractory multiple myeloma","volume":"123","author":"Shah","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2023.115875_bib175","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/cam4.4451","article-title":"Filanesib plus bortezomib and dexamethasone in relapsed\/refractory t(11;14) and 1q21 gain multiple myeloma","volume":"11","author":"Pan","year":"2022","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejmech.2023.115875_bib176","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/21541264.2022.2108302","article-title":"BRD4: a general regulator of transcription elongation","volume":"13","author":"Altendorfer","year":"2022","journal-title":"Transcription"},{"key":"10.1016\/j.ejmech.2023.115875_bib177","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1111\/febs.16580","article-title":"BRD4 and MYC: power couple in transcription and disease","volume":"290","author":"Kotekar","year":"2022","journal-title":"FEBS J,"},{"key":"10.1016\/j.ejmech.2023.115875_bib178","article-title":"BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer","volume":"119","author":"Liu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2023.115875_bib179","article-title":"Post-translational modifications of BRD4: therapeutic targets for tumor","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2023.115875_bib180","series-title":"Nitroxoline Shows Antimyeloma Activity by Targeting the TRIM25\/p53 Axle","first-page":"28","author":"Mao","year":"2017"},{"key":"10.1016\/j.ejmech.2023.115875_bib181","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720932686","article-title":"BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis","volume":"11","author":"Li","year":"2020","journal-title":"Therapeutic Advances in Hematology"},{"key":"10.1016\/j.ejmech.2023.115875_bib182","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215647","article-title":"Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myeloma","volume":"537","author":"Wang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2023.115875_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2023.115875_bib184","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science1108367","article-title":"Structural bioinformatics-based design of selective, irreversible kinase inhibitors","volume":"308","author":"Cohen","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115875_bib185","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.16614","article-title":"The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma","volume":"191","author":"Liang","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2023.115875_bib186","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/leu.2011.60","article-title":"The serine\/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells","volume":"25","author":"Asano","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2023.115875_bib187","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/leu.2014.147","article-title":"Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma","volume":"29","author":"Hiasa","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2023.115875_bib188","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.3390\/cancers13174304","article-title":"PIM kinases in multiple myeloma","volume":"13","author":"Wu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2023.115875_bib189","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s12185-021-03096-9","article-title":"A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and\/or refractory multiple myeloma","volume":"113","author":"Iida","year":"2021","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ejmech.2023.115875_bib190","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3390\/cells11132058","article-title":"Sphingosine-1-Phosphate (S1P) and S1P signaling pathway modulators, from current insights to future perspectives","volume":"11","author":"Bravo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2023.115875_bib191","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/s41423-022-00911-z","article-title":"Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis","volume":"19","author":"Lau","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ejmech.2023.115875_bib192","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neo.2021.11.009","article-title":"Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition","volume":"24","author":"Bennett","year":"2022","journal-title":"Neoplasia"},{"issue":"24","key":"10.1016\/j.ejmech.2023.115875_bib193","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3892\/ol.2022.13231","article-title":"Potential of a sphingosine 1-phosphate receptor antagonist and sphingosine kinase inhibitors as targets for multiple myeloma treatment","volume":"23","author":"Tanaka","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejmech.2023.115875_bib194","series-title":"Advances in Pharmacology","first-page":"95","article-title":"Chapter Four - sphingosine-1-phosphate and Sphingosine-1-phosphate receptors in the cardiovascular system: pharmacology and clinical implications","author":"Spampinato","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115875_bib195","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1038\/s41375-021-01271-9","article-title":"JunB is a key regulator of multiple myeloma bone marrow angiogenesis","volume":"35","author":"Fan","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2023.115875_bib196","article-title":"Non-coding RNA-mediated autophagy in cancer: a protumor or antitumor factor?","volume":"1876","author":"Liang","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2023.115875_bib197","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3892\/or.2022.8390","article-title":"Long non-coding RNAs interact with RNA-binding proteins to regulate genomic instability in cancer cells","volume":"48","author":"Yang","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2023.115875_bib198","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/bmm-2021-0682","article-title":"Clinical potential of long non-coding RNA LINC01133 as a promising biomarker and therapeutic target in cancers","volume":"16","author":"Sharma","year":"2022","journal-title":"Biomarkers Med."},{"key":"10.1016\/j.ejmech.2023.115875_bib199","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/1440-1681.13641","article-title":"Effects of polyphenols on ncRNAs in cancer\u2014an update","volume":"49","author":"Veeraraghavan","year":"2022","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.ejmech.2023.115875_bib200","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","article-title":"The biogenesis, biology and characterization of circular RNAs","volume":"20","author":"Kristensen","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2023.115875_bib201","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ymeth.2022.07.011","article-title":"Advances in detecting N6-methyladenosine modification in circRNAs","volume":"205","author":"Ma","year":"2022","journal-title":"Methods"},{"key":"10.1016\/j.ejmech.2023.115875_bib202","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s10020-021-00421-0","article-title":"Long non-coding RNA XIST: a novel oncogene in multiple cancers","volume":"27","author":"Yang","year":"2021","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejmech.2023.115875_bib203","series-title":"Next RNA Therapeutics: the Mine of Non-coding","author":"Garbo","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115875_bib204","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/15476286.2022.2062846","article-title":"Mechanisms of non-coding RNA-modulated alternative splicing in cancer","volume":"19","author":"Wang","year":"2022","journal-title":"RNA Biol."},{"key":"10.1016\/j.ejmech.2023.115875_bib205","doi-asserted-by":"crossref","first-page":"10667","DOI":"10.1007\/s11033-022-07668-8","article-title":"CircRNAs: novel therapeutic targets in multiple myeloma","volume":"49","author":"Zhou","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejmech.2023.115875_bib206","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41417-020-00291-4","article-title":"Roles of miRNA dysregulation in the pathogenesis of multiple myeloma","volume":"28","author":"Chen","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ejmech.2023.115875_bib207","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/path.5852","article-title":"Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by expression of lncRNAs","volume":"256","author":"Saltarella","year":"2022","journal-title":"J. Pathol."},{"key":"10.1016\/j.ejmech.2023.115875_bib208","series-title":"Small Molecules in Hematology","first-page":"133","article-title":"Ibrutinib","author":"Charalambous","year":"2018"},{"key":"10.1016\/j.ejmech.2023.115875_bib209","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106037","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update","volume":"175","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2023.115875_bib210","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317731369","article-title":"Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-\u03baB and STAT3","volume":"40","author":"Ma","year":"2018","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ejmech.2023.115875_bib211","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1570163819666220331095744","article-title":"Cancer chemotherapy via natural bioactive compounds","volume":"19","author":"Pathak","year":"2022","journal-title":"Curr. Drug Discov. Technol."},{"key":"10.1016\/j.ejmech.2023.115875_bib212","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1039\/D2FO01663J","article-title":"Potential roles and molecular mechanisms of phytochemicals against cancer","volume":"13","author":"Zheng","year":"2022","journal-title":"Food Funct."},{"key":"10.1016\/j.ejmech.2023.115875_bib213","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.2174\/1871520622666220425133936","article-title":"Promising role of phytochemicals in the prevention and treatment of cancer","volume":"22","author":"Unnisa","year":"2022","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115875_bib214","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/1440-1681.12546","article-title":"Multifaceted ability of naturally occurring polyphenols against metastatic cancer","volume":"43","author":"Zhou","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.ejmech.2023.115875_bib215","doi-asserted-by":"crossref","first-page":"11712","DOI":"10.3390\/ijms231911712","article-title":"Polyphenols as potent epigenetics agents for cancer","volume":"23","author":"Rajendran","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115875_bib216","doi-asserted-by":"crossref","first-page":"10244","DOI":"10.3390\/ijms231810244","article-title":"Combination therapy using polyphenols: an efficient way to improve antitumoral activity and reduce resistance","author":"Vladu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115875_bib217","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1011435","article-title":"Modern aspects of the use of natural polyphenols in tumor prevention and therapy","volume":"10","author":"Sufianova","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2023.115875_bib218","article-title":"Active components of traditional Chinese medicinal material for multiple myeloma: current evidence and future directions","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115875_bib219","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-020-04170-5","article-title":"Artemisinin-type drugs for the treatment of hematological malignancies","volume":"87","author":"Mancuso","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115875_bib220","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.cclet.2021.11.056","article-title":"Precisely engineering a dual-drug cooperative nanoassembly for proteasome inhibition-potentiated photodynamic therapy","volume":"33","author":"Yang","year":"2022","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115875_bib221","article-title":"Melphalan-loaded methoxy poly(ethylene glycol)-poly(D,L-lactide) copolymer nanomicelles in the treatment of multiple myeloma","author":"Chen","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115875_bib222","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2022.06.001","article-title":"J. Han, Fluorine-containing drugs approved by the FDA in 2021","volume":"34","author":"He","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115875_bib223","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","article-title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma","volume":"13","author":"Vo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115875_bib224","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40364-021-00296-7","article-title":"SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma","volume":"9","author":"Wu","year":"2021","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ejmech.2023.115875_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117971","article-title":"SR18292 exerts potent antitumor effects in multiple myeloma via inhibition of oxidative phosphorylation","volume":"256","author":"Xiang","year":"2020","journal-title":"Life Sci."},{"issue":"No 21","key":"10.1016\/j.ejmech.2023.115875_bib226","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.28073","article-title":"TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan","volume":"12","author":"H\u00e5land","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2023.115875_bib227","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.3390\/cancers14081955","article-title":"Mitochondrial Kv1.3 channels as target for treatment of multiple myeloma","volume":"14","author":"Kadow","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2023.115875_bib228","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54695-w","article-title":"DPP8 is a novel therapeutic target for multiple myeloma","volume":"9","author":"Sato","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.115875_bib229","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.canlet.2021.08.009","article-title":"Albendazole inhibits NF-\u03baB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma","volume":"520","author":"Yi","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2023.115875_bib230","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2021.05.001","article-title":"Resveratrol for cancer therapy: challenges and future perspectives","volume":"515","author":"Ren","year":"2021","journal-title":"Cancer Lett."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:56:45Z","timestamp":1759330605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423008425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":230,"alternative-id":["S0223523423008425"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115875","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in research on potential inhibitors of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115875"}}